Conditions: Breast Cancer Metastatic
Keywords: Breast cancer metastatic docetaxel PF-03084014
Enrollment: 30
Healthy volunteers: no

Brief summary:
This study is aimed to determine the tolerability of the PF-03084014 plus docetaxel combination in patients with advanced breast cancer. Preliminary information about the efficacy of the combination will also be collected.

Detailed description:

Arms:
arm 1: PF 03084014 will be administered orally, continuously, twice daily at doses from 80 to 150 mg in combination with docetaxel given every 3 weeks at doses from 75 to 100 mg/m\^2

Interventions: intervention 1: PF-03084014 intervention 2: PF-03084014 intervention 3: PF-03084014 intervention 4: Docetaxel intervention 5: Docetaxel
Intervention descriptions: intervention 1: Tablet, 10 mg, twice a day intervention 2: Tablet, 50 mg, twice a day intervention 3: Tablet, 100 mg, twice a day intervention 4: Solution for IV infusion 75 mg/m\^2, every 3 weeks intervention 5: Solution for IV infusion 100 mg/m\^2, every 3 weeks

Protocol document: